MODY patients exhibit shorter telomere length than non-diabetic subjects.
Andrea L MillanSofía I TroboAlejandro de DiosMartina Cerrato GarcíaMaría S PérezGloria Edith CerroneGustavo D FrechtelAriel P LópezPublished in: Diabetes/metabolism research and reviews (2020)
Both MODY2 and MODY3 types present telomere shortening, which, at least partly, responds to HbA1c and FPG levels. These findings suggest comparable mechanisms underlying the attrition of TL. Taken together, our results on aTL in MODY patients may provide a parameter relatively easy and inexpensive to quantify in order to measure the impact of high glucose levels and potentially carry out antidiabetic treatment with stricter targets.